Monographie - Benztropine mesylate

Последно актуализиране :
08/05/2024

Benztropine mesylate

Химична структура

Търговско наименование

Търговските имена са примерни и съставът на помощните вещества може да бъде различен в зависимост от държавата и лабораториите

Cogentin

Канада, Съединени Американски щати / САЩ

Библиография : Benztropine mesylate

	Вид	Публикация
188	Списание	Gibler B, Kim MS, Raleigh F. Visual compatibility of neuroleptics with anticholinergics or antihistamines in polyethylene syringes. Am J Hosp Pharm 1994 ; 51: 2709-2710.
229	Списание	Jackson CW, Cunningham K. Compatibility of haloperidol lactate with benztropine mesylate. Am J Hosp Pharm 1994 ; 51: 2962-2963.
479	Списание	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
496	Списание	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
1643	Списание	Raleigh F, Gibler B. Haldol-benztropine incompatibility. Hosp Pharm 1994 ; 29: 76.
1724	Списание	Elbe D, Condé C. Visual compatibility of various injectable neuroleptic agents with benztropine and lorazepam in polypropylene syringes. Can J Hosp Pharm 2001 ; 54: 102-105.
3012	Списание	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3964	Списание	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4319	Списание	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Списание	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213

Mentions Légales